FDA Public Meeting Report on "Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications".

MLA

Akbar, Mohammad, et al. “FDA Public Meeting Report on ‘Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications.’” Journal of Clinical Pharmacology, vol. 58, no. 12, Dec. 2018, pp. 1655–65. EBSCOhost, https://doi.org/10.1002/jcph.1285.

APA

Akbar, M., Berry-Bibee, E., Blithe, D. L., Day, R. S., Edelman, A., Höchel, J., Jamshidi, R., Kim, M.-J., Li, L., Purohit, V. S., Turpin, J. A., Scott, P. E., Strauss, D. G., Sun, H., Tepper, N. K., Zhang, L., & Yu, C. (2018). FDA Public Meeting Report on “Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications.” Journal of Clinical Pharmacology, 58(12), 1655–1665. https://doi.org/10.1002/jcph.1285

Chicago

Akbar, Mohammad, Erin Berry-Bibee, Diana L Blithe, Ruth S Day, Alison Edelman, Joachim Höchel, Roxanne Jamshidi, et al. 2018. “FDA Public Meeting Report on ‘Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications.’” Journal of Clinical Pharmacology 58 (12): 1655–65. doi:10.1002/jcph.1285.